The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa

por Frew, John W., Singh, N., Jiang, C. S., Vaughan, R., Krueger, J. G.
Publicado 2021

Signalling of multiple interleukin (IL)‐17 family cytokines via IL‐17 receptor A drives psoriasis‐related inflammatory pathways

por Tollenaere, M.A.X., Hebsgaard, J., Ewald, D.A., Lovato, P., Garcet, S., Li, X., Pilger, S.D., Tiirikainen, M.L., Bertelsen, M., Krueger, J.G., Norsgaard, H.
Publicado 2021

Human keratinocyte growth factor effects in a porcine model of epidermal wound healing

por Staiano-Coico, L., Krueger, J. G., Rubin, J. S., D'limi, S., Vallat, V. P., Valentino, L., Fahey, T., Hawes, A., Kingston, G., Madden, M. R., Mathwich, M., Gottlieb, A., Aaronson, S. A.
Publicado 1993

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐...

por Oliver, R., Krueger, J.G., Glatt, S., Vajjah, P., Mistry, C., Page, M., Edwards, H., Garcet, S., Li, X., Dizier, B., Maroof, A., Watling, M., el Baghdady, A., Baeten, D., Ionescu, L., Shaw, S.
Publicado 2021

A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate pla...

por Berstein, G., Zhang, Y., Berger, Z., Kieras, E., Li, G., Samuel, A., Yeoh, T., Dowty, H., Beaumont, K., Wigger‐Alberti, W., von Mackensen, Y., Kroencke, U., Hamscho, R., Garcet, S., Krueger, J. G., Banfield, C., Oemar, B.
Publicado 2020